Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Drop in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 1,790,000 shares, a decline of 19.0% from the October 15th total of 2,210,000 shares. Based on an average daily trading volume, of 458,300 shares, the short-interest ratio is presently 3.9 days. Approximately 2.1% of the shares of the stock are short sold.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently bought and sold shares of CMPX. SG Americas Securities LLC boosted its stake in shares of Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after purchasing an additional 5,515 shares during the period. Rhumbline Advisers increased its stake in Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after buying an additional 12,315 shares during the period. Rovin Capital UT ADV purchased a new position in Compass Therapeutics in the 3rd quarter valued at approximately $25,000. Intech Investment Management LLC purchased a new position in Compass Therapeutics in the 3rd quarter valued at approximately $30,000. Finally, Geode Capital Management LLC grew its stake in shares of Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after acquiring an additional 19,095 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Stock Down 13.2 %

Shares of CMPX traded down $0.21 during trading on Friday, reaching $1.38. 1,348,934 shares of the company traded hands, compared to its average volume of 455,768. The stock has a 50-day simple moving average of $1.75 and a 200-day simple moving average of $1.42. The stock has a market cap of $189.87 million, a PE ratio of -3.73 and a beta of 0.92. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. On average, equities research analysts predict that Compass Therapeutics will post -0.37 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Wednesday, August 7th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $5.00 to $4.00 in a report on Friday. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, November 11th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Monday, September 16th. Finally, Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.75.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.